SummitTX Capital’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
SummitTX Capital's TVTX Position: Q3 2026 in Review
SummitTX Capital sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 96,018 shares — an estimated $5.45M sold.
SummitTX Capital first reported a position in TVTX in Q1 2025 and held it in 2 quarters. The position peaked at $5.45M in Q2 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- SummitTX Capital reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
- SummitTX Capital sold 96,018 Travere Therapeutics shares in Q3 2026, an estimated $5.45M.
- SummitTX Capital first reported a position in Travere Therapeutics in Q1 2025 and held it in 2 quarters.
- SummitTX Capital's Travere Therapeutics position peaked at $5.45M in Q2 2026.
- 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on SummitTX Capital's 13F filing for Q3 2026, filed 16 Nov 2026.